Oblimersen sodium (Genasense™) is an antisense oligodeoxynucleotide specific for the antiapoptotic protein Bcl-2, which could enhance the sensitivity of leukemic cells to chemotherapy in this ...

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis ... injection over 12 weeks on top of high-dose statin therapy. AZ said the data show that AZD8233 could become ...

antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA ...

The oligonucleotides market has gained significant traction in recent years due to its critical role in molecular biology, genetics, and therapeutics. Oligonucleotides, short DNA or RNA molecules, are ...